CVE:KNE Kane Biotech (KNE) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free KNE Stock Alerts C$0.10 0.00 (0.00%) (As of 11:37 AM ET) Add Compare Share Share Today's RangeC$0.10▼C$0.1150-Day RangeC$0.08▼C$0.1152-Week RangeC$0.05▼C$0.14Volume143,500 shsAverage Volume59,912 shsMarket CapitalizationC$13.18 millionP/E RatioN/ADividend Yield3.08%Price TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesStock AnalysisChartEarningsHeadlines Get Kane Biotech alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Kane Biotech Stock (CVE:KNE)Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; and animal and human wound care solutions under the DispersinB name. It also offers scalp care products under the DermaKB brand name; and wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, Aledex, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.Read More KNE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KNE Stock News HeadlinesMarch 27, 2024 | finance.yahoo.comKane Biotech Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 20, 2024 | finance.yahoo.comKane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal HealthMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 8, 2024 | tmcnet.comKane Biotech Receives Bioscience Association Manitoba Company of the Year AwardFebruary 24, 2024 | msn.comChicago Blackhawks brace for Patrick Kane’s return — as a Detroit Red Wing: ‘It’s definitely weird’January 31, 2024 | finanznachrichten.deKane Biotech Inc.: Kane Biotech Files New Patent on revyve Antimicrobial Wound Gel SprayJanuary 31, 2024 | financialpost.comKane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel SprayJanuary 31, 2024 | stockhouse.comKane Biotech Files New Patent on revyve(TM) Antimicrobial Wound Gel SprayMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… January 25, 2024 | markets.businessinsider.comKane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care SymposiumJanuary 18, 2024 | finance.yahoo.comKane Biotech Announces Special Meeting of ShareholdersDecember 29, 2023 | finance.yahoo.comKane Biotech Announces Correction to Press ReleaseNovember 29, 2023 | finanznachrichten.deKane Biotech Inc.: Kane Biotech Announces Improved Third Quarter 2023 Financial ResultsNovember 28, 2023 | finance.yahoo.comKane Biotech Announces Improved Third Quarter 2023 Financial ResultsNovember 2, 2023 | finanznachrichten.deKane Biotech Inc.: Kane Biotech and ProgenaCare Global Launch Newly Rebranded revyve Antimicrobial Wound Gel at Advanced Wound Care Fall ForumNovember 2, 2023 | markets.businessinsider.comKane Biotech and ProgenaCare Global Launch Newly Rebranded revyve™ Antimicrobial Wound Gel at Advanced Wound Care Fall ForumNovember 2, 2023 | msn.comHarry Kane’s first ‘Klassiker’ at Bayern overshadowed by de Ligt injury and shock cup exitOctober 25, 2023 | stockhouse.comKane Biotech to Exhibit at Symposium on Advanced Wound Care Fall ForumOctober 17, 2023 | theglobeandmail.comClosing Bell: Kane Biotech Inc flat on Tuesday (KNE)September 12, 2023 | finance.yahoo.comKane Biotech Announces Closing of Fully Subscribed Private Placement Offering and Amendments to its Credit FacilityAugust 30, 2023 | finanznachrichten.deKane Biotech Inc.: Kane Biotech Announces Second Quarter 2023 Financial ResultsAugust 29, 2023 | finance.yahoo.comKane Biotech Announces Second Quarter 2023 Financial ResultsAugust 5, 2023 | theglobeandmail.comClosing Bell: Kane Biotech Inc down on Thursday (KNE)August 3, 2023 | finance.yahoo.comKane Biotech Announces Private Placement Offering and Proposed Amendments to its Credit FacilityAugust 2, 2023 | finance.yahoo.comKane Biotech Engages Research Capital to Conduct Strategic Review of STEM Animal HealthJune 23, 2023 | finance.yahoo.comKane Biotech Announces Issuance of Restricted Share UnitsMay 26, 2023 | finanznachrichten.deKane Biotech Inc.: Kane Biotech Announces First Quarter 2023 Financial ResultsSee More Headlines Receive KNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kane Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:KNE CUSIPN/A CIKN/A Webwww.kanebiotech.com Phone+1-204-4531301FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-4,320,000.00 Net Margins-157.48% Pretax MarginN/A Return on EquityN/A Return on Assets-32.70% Debt Debt-to-Equity Ratio1,164.24 Current Ratio0.37 Quick Ratio0.39 Sales & Book Value Annual SalesC$2.74 million Price / Sales4.81 Cash FlowC$0.01 per share Price / Cash Flow8.50 Book ValueC($0.07) per share Price / Book-1.43Miscellaneous Outstanding Shares131,840,000Free FloatN/AMarket CapC$13.18 million OptionableNot Optionable Beta0.56 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Marc EdwardsPresident, CEO & DirectorMr. Ray DupuisChief Financial OfficerMr. Kevin ColePresident & CEO of STEM Animal Health IncMr. Dena MehrabanGeneral Manager of STEM Animal Health IncDr. Robert B. Huizinga CNeph(C) (Age 58)M.Sc., MSc(Epi), Ph.D., R.N., RN NNC, Executive Chairman & Member of Scientific Advisory Board Dr. Gregory S. Schultz Ph.D. (Age 74)Chief Scientific Officer & Member of Scientific Advisory Board Lorne GorberInvestor RelationsMs. Lori ChristofalosVice President of Quality & ComplianceMs. Wendy NachtigallDirector of MarketingNicole SendeyInvestor Relations AdviserMore ExecutivesKey CompetitorsAeterna ZentarisTSE:AEZSIMVTSE:IMVResverlogixTSE:RVXNeptune Wellness SolutionsTSE:NEPTReunion NeuroscienceTSE:REUNView All CompetitorsInsidersRichard J. RenaudBought 3,125,000 shares on 9/11/2023Total: C$250,000.00 ($0.08/share) KNE Stock Analysis - Frequently Asked Questions How have KNE shares performed in 2024? Kane Biotech's stock was trading at C$0.08 at the start of the year. Since then, KNE stock has increased by 25.0% and is now trading at C$0.10. View the best growth stocks for 2024 here. When is Kane Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024. View our KNE earnings forecast. How do I buy shares of Kane Biotech? Shares of KNE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:KNE) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kane Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.